Table 2.
Influence of FGF21 administration on the masses of the body, fat, and liver in obese Ay male and female mice. Results are presented as mean ± SE for the indicated number of mice. Data were analyzed with two-way ANOVA.
| Ay Males | Ay Females | p ANOVA | |||
|---|---|---|---|---|---|
| PBS (n = 7) | FGF21 (n = 7) | PBS (n = 6) | FGF21 (n = 6) | ||
| BW (g) | 46.9 ± 0.6 | 45.7 ± 1.2 | 46.5 ± 1.45 | 48.2 ± 0.83 | ns |
| Lean mass (g) | 28.1 ± 0.4 | 28.0 ± 0.3 | 23.8 ± 0.6 # | 23.8 ± 0.5 # | s |
| Fat mass (g) | 16.7 ± 0.6 | 16.0 ± 1.0 | 20.8 ± 1.0 # | 22.5 ± 0.7 # | s |
| Liver weight (g) | 2.67 ± 0.06 | 2.15 ± 0.09 * | 1.98 ± 0.08 # | 2,12 ± 0.06 | s, e, s*e |
| iBAT weight (g) | 0.185 ± 0.025 | 0.164 ± 0.017 | 0.179 ± 0.023 | 0.201 ± 0.026 | ns |
* p < 0.05, FGF21 vs. PBS, males; # p < 0.05, females vs. males, post hoc Newman–Keuls test. Significant influence (p < 0.05) of factors “e” (administration of PBS or FGF21), “s” (sex), and “s*e”, or non-significant “ns”, two-way ANOVA, are indicated in the last column.